Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Nov 3, 2022
- Accession no.
- 0001209191-22-055471
- Filed
- Nov 3, 2022, 2:50 PM ET
- Trade date
- Oct 31-Nov 2, 2022
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $12.0K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +7,500 | $0.45 | +$3,375 | 11,968,257 | Direct | |
| Nov 1, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +5,000 | $0.43 | +$2,150 | 11,973,257 | Direct | |
| Nov 2, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +15,000 | $0.43 | +$6,450 | 11,988,257 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.